AstraZeneca's experimental drug, tozorakimab, for chronic obstructive pulmonary disease (COPD) has shown promising results in two late-stage trials, significantly reducing flare-ups in a wide range of patients. The detailed data from these trials reinforce expectations for the drug to achieve peak annual sales exceeding $5 billion, contributing to AstraZeneca's goal of reaching $80 billion in revenue by 2030.
Tozorakimab, administered once every four weeks, reduced moderate and severe COPD flare-ups by 29% and 34% respectively in former smokers. For the broader population including current and former smokers, reductions were 30% and 29%. The drug also demonstrated efficacy across different blood eosinophil counts, reducing flare-ups by 23% in patients with counts below 150, 34% in those at or above 150, and 43% in those at or above 300. This broad applicability is seen as a key differentiator, as existing biologics for COPD, such as Regeneron and Sanofi's Dupixent and GSK's Nucala, are limited to patients with high eosinophil levels.
The drug works by blocking the IL-33 protein, which drives inflammation and mucus production in COPD. While previous IL-33 treatments have had limited success, AstraZeneca believes its approach, targeting two distinct IL-33 pathways, is more effective. The Food and Drug Administration has accepted tozorakimab for priority review, with U.S. approval anticipated in the first quarter of 2027. AstraZeneca's president of biopharmaceuticals, Ruud Dobber, emphasized that a large population of COPD patients could benefit, potentially changing the treatment paradigm.
Despite the positive results, questions remain regarding tozorakimab's placement relative to existing biologics for COPD patients with high eosinophil levels, as no head-to-head studies have been conducted. Dr. Meilan Han, a study investigator, highlighted the need for more subgroup data to guide treatment decisions. COPD affects an estimated 16 million to 26 million Americans and is the fifth-leading cause of death in the U.S.
